After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
1d
MedPage Today on MSNOnce-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly DosingA once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
2d
Zacks Investment Research on MSNVKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug SupplyViking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and ...
Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...
A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...
2d
Zacks.com on MSNRHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity DrugRoche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results